Certara and The University of Manchester co-host inaugural model-based personalized drug dosing in healthcare conference
Clinical healthcare researchers, academic, and industry experts from eight countries collaborate to advance the goal of identifying the right drug dose for each patient.
Certara, in partnership with The University of Manchester, successfully organized the first-ever Health Care Summit on Model-based Precision Dosing on 19-20 May in the UK. Precision dosing is a key and proactive step toward achieving the goals of precision medicine, a global objective supported by world leaders, including President Obama under the Precision Medicine Initiative.
“Through its modeling and simulation work, Certara has been working toward the goal of precision dosing — providing the right drug dose to maximize therapeutic benefit, while reducing risk for each individual patient,” said Certara CEO Edmundo Muniz. “Through this Summit and the 15 examples which were presented that showcased the successful use of modeling and simulation in the hospital research environment, we are confident that precision dosing in healthcare will become mainstream shortly.”
Professor Kay Marshall, head of the Manchester Pharmacy School and a speaker at the conference, said: “Everyone is different and this means that they react to drugs in different ways. The emerging precision dosing field harnesses the explosion of genomic data and various markers of bodily functions using mathematical modeling to ensure that individuals get the best possible treatment.”
Speakers from eight countries, representing research institutions, academia, pharmaceutical companies, former regulators, and legal authorities spoke at the Summit. Sessions were organized around special populations representing the most fragile and complex population cohorts, including oncology, HIV, pediatric, obese, renally-impaired, cell transplant, and adolescent psychiatric patients and pregnant women. In addition to demonstrating how modeling and simulation facilitated individualized dosing, the conference focused on linking personalized dosing and its impact on public health.
Certara Chief Scientific Officer Amin Rostami, who also serves as the chair of systems pharmacology at The University of Manchester, said: “We now understand more fully the sources of variability, the individual characteristics of each patient, which can drive dosing decisions. The successful case studies shared at this Summit demonstrate that we are now ready to take the next step toward individualized dosing in everyday health care.”
Related News
-
News CPHI Frankfurt: Interview with Marcelo Cruz, Vice President, Business Development & Marketing at Tjoapack
In this series of interviews, we caught up with some of the exhibitors at CPHI Frankfurt to discover what innovations are being brought to the pharmaceutical industry this year. Here we chat with Marcelo Cruz of Tjoapack to discuss how global events ar... -
News CPHI Frankfurt 2022: Innovator Interviews – Bioiberica
In this series of interviews, we speak to the companies on the CPHI Frankfurt show floor who are driving innovation in pharma for a better healthcare future. We caught up with Mónica Gómez Navarro (Marketing Manager Branded Ingredients), ... -
News CPHI Frankfurt 2022: Innovator Interview – Procaps Group
In this series of interviews, we speak to the companies on the CPHI Frankfurt show floor who are driving innovation in pharma for a better healthcare future. We interviewed Rosella Del Vecchio Herrera, Marketing Director at Procaps Group, to discover h... -
News From the floor - CPHI Frankfurt 2022
The live blog from the people on the ground at CPHI Frankfurt - covering all stand-out news, memorable moments, and keynote updates from the 2022 event. -
News How to Commercialise an Advanced Therapy: Connect to Frankfurt on-demand
In this Connect to Frankfurt session, Andrea Zobel, Senior Director, Personalized Supply Chain at World Courier (Berlin Germany), Melissa Lattanzi, VP Emerging Therapies at AmerisourceBergen (King of Prussia, USA), and Hans-Peter Scherzer, Customer Suc... -
News CDMO - Health is a Joint Project: Connect to Frankfurt on-demand
In this Connect to Frankfurt session, Emanuele Agnese, Business Development Manager and Pietro Allegrini, R&D Director at Indena, present the ways in which a reliable manufacturing partner in the pursuit of better health outcomes for patients and pharm... -
News Streamlined Development for Efficient Production of Bispecific Molecules: Connect to Frankfurt on-demand
In this Connect to Frankfurt session, Séverine Fagète, VP, Cell Line Development Services at Selexis (Geneva, Switzerland), and Brandon Brino (Durham, USA), Process Development Scientist and Group Leader at KBI Biopharma, present an overv... -
News MDR – How to collect post-market clinical follow-up data (PMCF): Connect to Frankfurt on-demand
In this Connect to Frankfurt session, Philipp Annecke, Junior Key Account Manager and Heinrich Martens, VP Regulatory Affairs of Fresenius Kabi (Bad Homburg, Germany) present guidances from the Medical Devices Regulation on clinical data evaluatio...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance